#South Korea #Seoul #Caris Life Sciences #Precision Oncology #IASLC 2026

Caris Life Sciences Brings Cutting-Edge Research to IASLC 2026

Caris Life Sciences®, a prominent TechBio company listed on NASDAQ under the symbol CAI, is set to present groundbreaking research at the IASLC 2026 World Conference on Lung Cancer, scheduled from September 12 to 15 in Seoul, South Korea. The company is collaborating with the Caris Precision Oncology Alliance® to showcase seven comprehensive studies that delve into the intricacies of lung cancer biology and treatment strategies.

This year's conference is anticipated to be significant, as it underscores the pivotal role of advanced molecular profiling coupled with artificial intelligence in understanding lung cancer dynamics. The research includes two mini oral presentations, a poster tour, and multiple poster sessions. According to Dr. George W. Sledge, Jr., Chief Medical Officer at Caris Life Sciences, the findings underline the importance of large-scale datasets in unveiling critical insights into the therapeutic responses and biological underpinnings of cancer.

Highlights of the Research Presentations

Mini Oral Presentations

1. Impact of Protein Arginine Methyltransferase 5 (PRMT5) Expression and MTAP Deletion on Survival in NSCLC
- Session MO05 on September 14, 2026
- In an analysis involving over 39,000 non-small cell lung cancer (NSCLC) samples, tumors with MTAP deletions exhibited elevated levels of PRMT5. These tumors were associated with poorer overall survival rates and a less favorable immune microenvironment.

2. Racial and Ethnic Disparities in Immunotherapy Biomarkers in NSCLC
- Session MO13 on September 15, 2026
- This analysis of over 43,000 NSCLC samples highlighted significant differences in clinical outcomes based on race. Notably, non-Hispanic Asian Pacific Islander patients demonstrated better survivability compared to non-Hispanic White patients, prompting discussions on the implications for personalized treatment strategies.

Poster Tour

• - Transcriptomic Subtypes in Mesothelioma

- Session PT2.05 on September 14, 2026
- Research involving 386 mesothelioma samples identified distinct transcriptomic clusters, which may guide more personalized treatment approaches if findings are validated through prospective studies.

Additional Poster Presentations

In addition to the featured presentations, several posters will expand on topics such as:

• - Germline variants identified in 12.2% of 3,609 NSCLC patients, stressing the importance of considering inherited gene alterations in therapeutic decisions.
• - A study showing how ITGB6 expression affects survival outcomes in NSCLC, with differential impacts noted based on histology and genomic contexts.

These research findings not only advance the understanding of lung cancer but also offer the potential to enhance clinical decision-making in a rapidly evolving field.

About Caris Life Sciences

Based in Irving, Texas, Caris Life Sciences is focused on revolutionizing healthcare through precision medicine. With services extending globally, the company integrates advanced molecular profiling, artificial intelligence, and machine learning to analyze complex disease pathways. Their commitment is to push the boundaries of early detection and maximizing treatment efficacy, underscoring their mission to elevate patient care through innovation.

The significant research presented at the IASLC 2026 will be available for discussion at Caris' exhibition booth #813, further presenting insights into the future of cancer treatment and patient management, reflecting Caris’ leading role in precision oncology research and applications.